Improving Access to Medicines — Pharmaceutical Benefits Scheme — new and amended listings

This measure provides for new and amended listings to the Pharmaceutical Benefits Scheme (PBS).

Information update: This Budget measure is not subject to the passage of legislation.

Description of Measure

This measure provides for new and amended listings to the Pharmaceutical Benefits Scheme (PBS).

These changes give eligible Australians and overseas visitors more affordable access to vital medicines.

New listings

From 1 February 2017:

  • ceritinib - for the treatment of ALK-positive non-small cell lung cancer
  • ixekizumab - for the treatment of severe chronic plaque psoriasis
  • olaparib - for the treatment of high grade serious ovarian cancer
  • riociguat - for the treatment of pulmonary arterial hypertension.

From 1 April 2017:

  • paliperidone - for the treatment of schizophrenia
  • brentuximab vedotin - for the treatment of relapsed or refractory Hodgkin lymphoma in transplant naïve patients
  • brentuximab vedotin - for the treatment of relapsed or refractory Hodgkin lymphoma in transplant experienced patients
  • vismodegib - for the treatment of locally advanced or metastatic basal cell carcinoma
  • calcipotriol + betamethasone dipropionate - for the treatment of chronic stable plaque psoriasis.

From 1 May 2017:

  • blinatumomab - for the treatment of relapsed or refractory acute lymphoblastic leukaemia
  • nintedanib - for the treatment of idiopathic pulmonary fibrosis
  • daclizumab - for the treatment of multiple sclerosis.

From 1 June 2017:

  • sacubitril + valsartan - for the treatment of chronic heart failure.

Amended listings

From 1 February 2017:

  • dasatinib - for the treatment of chronic myeloid leukaemia, with flow on changes to imatinib.

From 1 April 2017:      

  • pembrolizumab - for the treatment of malignant melanoma.

From 1 May 2017:

  • varenicline, bupropion and nicotine replacement therapy - for the treatment of nicotine dependence
  • ivacaftor - for the treatment of cystic fibrosis.

From 1 June 2017:

  • adalimumab and infliximab - for the treatment of ulcerative colitis.

Relistings

From 1 April 2017:

  • ferrous fumarate and ferrous fumarate with folic acid - for the treatment of iron deficiency and iron deficiency anaemias.

From 1 May 2017:

  • chloramphenicol - for the treatment of eye infections.

Questions and answers

Whom does this measure affect?

This measure affects Australian residents and eligible overseas visitors wanting to access these medicines under the PBS. This measure also affects health professionals who work with or prescribe these medicines.

What date will this measure start and finish?

These new and amended listings take effect from the dates listed above and are ongoing.

Page last updated: 15 May 2017

This information was printed Thursday 25 May 2017 from humanservices.gov.au/corporate/budget/budget-2017-18/improving-access-medicines/improving-access-medicines-pharmaceutical-benefits-scheme-new-and-amended-listings It may not include all of the relevant information on this topic. Please consider any relevant site notices at humanservices.gov.au/siteinformation when using this material.